Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

Celcuity’s stock jumps after Phase 3 trial shows gedatolisib slashes progression risk in breast cancer patients by up to 76%.

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

A Northeastern University researcher has identified a way to target two of the deadliest cancer types, melanoma and triple ...

Bone health management varies across hospitals for older women with early breast cancer who have inconsistent bone density ...

Breast cancer rates are on the rise, and doctors fear that alcohol could be a big reason why. CNN’s Meg Tirrell speaks to an ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Prolonged sitting time increases breast cancer risk in obese women, but physical activity may mitigate this association, ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Breast cancer rates among women are on the rise, and doctors are pointing to alcohol as a potential contributing factor.

A major investigation is under way into the care of thousands of breast cancer patients at a hospital trust. The County ...